ライフサイエンスコーパス: MMR vaccine

1 0.01) after the introduction of the two-dose MMR vaccine.

2 students had received at least two doses of MMR vaccine.

3 tolerability of this early administration of MMR vaccine.

4 ling data to support a routine third dose of MMR vaccine.

5 ed (P=.01) immune responses after 2 doses of MMR vaccine.

6 ible to receive the measles, mumps, rubella (MMR) vaccine.

7 nd/or receiving the measles, mumps, rubella (MMR) vaccine.

8 dents with 2 doses of measles-mumps-rubella (MMR) vaccine.

9 Students who had received a second dose of MMR vaccine 13 years or more before the outbreak had an

10 We identified 131 reports of MMR vaccine administered to a pregnant woman; the majori

11 do not support a causal association between MMR vaccine and autism.

12 ), Polio, Measles, Rubella, Mumps, trivalent MMR vaccine and Haemophilus influenza type B (HiB) vacci

13 age 18 months, compared with risk following MMR vaccine and vaccine uptake for 2-dose MCV and single

14 g no link between the measles-mumps-rubella (MMR) vaccine and autism spectrum disorders (ASD), belief

15 wo doses of the measles, mumps, and rubella (MMR) vaccine; and proportions with medical or personal-b

16 Two doses of measles, mumps, and rubella (MMR) vaccine are 97% effective against measles, but wani

17 ar-old Finnish children vaccinated once with MMR vaccine at 11-19 months of age.

18 Febrile seizures occurred after dose 1 of MMR vaccine at a known low increased risk (RI, 2.71; 95%

19 ers considered 6612 (16%) to be eligible for MMR vaccine at the time of pretravel consultation.

20 in historical cohorts recommended to receive MMR vaccine before school entry, and on-time vaccination

21 accine and 8 to 14 days after the receipt of MMR vaccine, but these risks do not appear to be associa

22 he known effects of the measles component of MMR vaccine-but not in the 15- to 35-day period (relativ

23 12 receive 2 doses of measles-mumps-rubella (MMR) vaccine by 2001.

24 a, health officials implemented a widespread MMR vaccine campaign.

25 Measles-mumps-rubella (MMR) vaccines containing the Urabe strain of mumps were

26 From 2001 through 2008, national 1-dose MMR vaccine coverage among children 19-35 months of age

27 A 5% decline in MMR vaccine coverage in the United States would result i

28 hs in municipalities with routine first-dose MMR vaccine coverage of <90%.

29 For infants who received an early MMR vaccine dose (n = 962), we asked for information abo

30 status and years since receipt of the second MMR vaccine dose.

31 nely, the first measles, mumps, and rubella (MMR) vaccine dose is given at 14 months of age in the Ne

32 of adults aged >/=19 years who received the MMR vaccine from 1 January 2003 to 31 July 2013.

33 Students who had received a third dose of MMR vaccine had a lower risk of mumps than did those who

34 TP) vaccine and measles, mumps, and rubella (MMR) vaccine has been associated with adverse neurologic

35 The combined measles, mumps, and rubella (MMR) vaccine has been successfully administered for >20

36 t the campaign to administer a third dose of MMR vaccine improved mumps outbreak control and that wan

37 period, VAERS received 3175 US reports after MMR vaccine in adults.

38 g introduction of the measles-mumps-rubella (MMR) vaccine in 1988.

39 vaccine as a combined measles-mumps-rubella (MMR) vaccine in 1999 and the implementation of measles i

40 e safety of the measles, mumps, and rubella (MMR) vaccine in adults.

41 f a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is unknown.

42 hildren who present with mild illnesses with MMR vaccine is a safe and efficacious practice.

43 The measles-mumps-rubella (MMR) vaccine is effective in eliciting a good antibody r

44 stigate whether measles, mumps, and rubella (MMR) vaccine may be causally associated with autism.

45 x, age, age at receipt of the second dose of MMR vaccine (MMR2), or time since receipt of MMR2 (P = .

46 verage of all schoolchildren with 2 doses of MMR vaccine, most states are well on their way toward th

47 wed by MMRV vaccine, 97 (24.8%) had received MMR vaccine only, and 16 (4.1%) had received neither vac

48 the measles-mumps-rubella (MMR) vaccine, the MMR vaccine only, and the expanded 2008 schedule.

49 with DTP vaccine, 137,457 vaccinations with MMR vaccine, or no recent vaccination.

50 Following introduction of a replacement MMR vaccine (Priorix; GlaxoSmithKline, London, United Ki

51 ears, and probably reflect the impact of the MMR vaccine programme and the use of more sensitive diag

52 MMR vaccine receipt (0, 1, 2 doses) between birth and 5

53 ings indicate no harmful association between MMR vaccine receipt and ASD even among children already

54 MMR vaccine receipt was not associated with an increased

55 e with or without the measles-mumps-rubella (MMR) vaccine, the MMR vaccine only, and the expanded 200

56 sceptible persons, and administration of the MMR vaccine to more than 10,000 persons.

57 icate that administration of TCVs and/or the MMR vaccine to rhesus macaques does not result in neurop

58 sted relative risk (RR) of ASD for 1 dose of MMR vaccine vs no vaccine was 0.76 (95% CI, 0.49-1.18; P

59 Receipt of MMR vaccine was associated with an increased risk of feb

60 children with older siblings, receipt of the MMR vaccine was not associated with increased risk of AS

61 ttributable to the administration of DTP and MMR vaccines was estimated to be 6 to 9 and 25 to 34 per

62 fter receipt of measles, mumps, and rubella (MMR) vaccine were tested for the ability to neutralize a

63 l, 97% had received at least one dose of the MMR vaccine, with 2.5% having personal-belief exemptions